We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Alexion Pharmaceuticals Inc | NASDAQ:ALXN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 182.50 | 183.00 | 185.00 | 0 | 00:00:00 |
From Feb 2020 to Feb 2025
By Adria Calatayud
AstraZeneca PLC said Friday that it has appointed Aradhana Sarin, currently executive vice-president and chief financial officer of Alexion Pharmaceuticals Inc., as its next CFO, replacing Marc Dunoyer.
The Cambridge, U.K.-based pharmaceutical giant--which is in the process of acquiring Alexion--said Mr. Dunoyer will retire from AstraZeneca's board, having served as CFO for more than seven years. He will become chief executive of Alexion and chief strategy officer of AstraZeneca.
The executive changes are conditional upon completion of the deal and will be effective on the later of Aug. 1 or the date of closing, AstraZeneca said.
AstraZeneca said its acquisition is expected to be completed in the third quarter, subject to receipt of certain regulatory approvals.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
June 04, 2021 02:33 ET (06:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Alexion Pharmaceuticals Chart |
1 Month Alexion Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
